Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome
Annals of the Rheumatic Diseases, Volume 81, No. 6, Year 2022
Notification
URL copied to clipboard!
Description
Objective To develop recommendations for cardiovascular risk (CVR) management in gout, vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD), Sjögren’s syndrome (SS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Methods Following European League against Rheumatism (EULAR) standardised procedures, a multidisciplinary task force formulated recommendations for CVR prediction and management based on systematic literature reviews and expert opinion. Results Four overarching principles emphasising the need of regular screening and management of modifiable CVR factors and patient education were endorsed. Nineteen recommendations (eleven for gout, vasculitis, SSc, MCTD, myositis, SS; eight for SLE, APS) were developed covering three topics: (1) CVR prediction tools; (2) interventions on traditional CVR factors and (3) interventions on disease-related CVR factors. Several statements relied on expert opinion because high-quality evidence was lacking. Use of generic CVR prediction tools is recommended due to lack of validated rheumatic diseases-specific tools. Diuretics should be avoided in gout and beta-blockers in SSc, and a blood pressure target <130/80 mm Hg should be considered in SLE. Lipid management should follow general population guidelines, and antiplatelet use in SLE, APS and large-vessel vasculitis should follow prior EULAR recommendations. A serum uric acid level <0.36 mmol/L (<6 mg/dL) in gout, and disease activity control and glucocorticoid dose minimisation in SLE and vasculitis, are recommended. Hydroxychloroquine is recommended in SLE because it may also reduce CVR, while no particular immunosuppressive treatment in SLE or urate-lowering therapy in gout has been associated with CVR lowering. Conclusion These recommendations can guide clinical practice and future research for improving CVR management in rheumatic and musculoskeletal diseases. © Author(s) (or their employer(s)) 2022.
Authors & Co-Authors
Atzeni, Fabiola
Italy, Messina
Università Degli Studi Di Messina
Boumpas, Dimitrios T.
Greece, Athens
Attikon University Hospital
Greece, Athens
National and Kapodistrian University of Athens
Brodin, Nina C.
Sweden, Stockholm
Karolinska Institutet
Sweden, Danderyd
Danderyds Sjukhus
Bruce, Ian N.
United Kingdom, Manchester
The University of Manchester
United Kingdom, Manchester
Manchester University Nhs Foundation Trust
González-Gay, Miguel Ángel
Spain, Santander
Universidad de Cantabria
Jacobsen, Soren Vidar
Denmark, Copenhagen
Rigshospitalet
Denmark, Copenhagen
Københavns Universitet
Marchiori, F.
Italy, Rome
Eular Pare Patient Research Partner
Mukhtyar, Chetan B.
United Kingdom, Norwich
Norfolk and Norwich University Hospitals Nhs Foundation Trust
Ramos-Casals, Manuel
Spain, Barcelona
Hospital Clinic Barcelona
Sattar, Naveed A.
United Kingdom, Glasgow
University of Glasgow
Schreiber, Karen Ingrid
Unknown Affiliation
Sciascia, Savino
Italy, Turin
Azienda Sanitaria Ospedaliera Molinette San Giovanni Battista Di Torino
Svenungsson, Elisabet
Sweden, Stockholm
Karolinska Institutet
Szekanecz, Zoltán A.
Hungary, Debrecen
Debreceni Egyetem
Tausche, Anne Kathrin
Germany, Dresden
Technische Universität Dresden
Tyndall, Alan D.
Switzerland, Basel
Universitat Basel
Voskuyl, Alexandre E.
Netherlands, Amsterdam
Vrije Universiteit Amsterdam
MacFarlane, Gary John
United Kingdom, Aberdeen
Nhs Grampian
Ward, Michael M.
United States, Bethesda
National Institutes of Health Nih
Nurmohamed, Michael T.
Netherlands, Amsterdam
Amsterdam Umc - University of Amsterdam
Tektonidou, Prof Maria G.
Greece, Athens
Laikon General Hospital
Greece, Athens
National and Kapodistrian University of Athens
Statistics
Citations: 81
Authors: 21
Affiliations: 24
Identifiers
Doi:
10.1136/annrheumdis-2021-221733
ISSN:
00034967
Research Areas
Health System And Policy
Noncommunicable Diseases
Study Design
Cross Sectional Study